Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Bipolar, Depression

In brief

The specific aim of this study is to evaluate the efficacy and tolerability of lisdexamfetamine in the adjunctive treatment of bipolar disorder.

Key facts

Study ID

NCT01131559

Run by

Lindner Center of HOPE

People needed

50

Starts

2010-01-01

Expected to finish

2014-02-01

Last updated by the study team

2014-03-05

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Subjects will meet DSM-IV-TR criteria bipolar I or II disorder,

You may not qualify if…

• Women who are pregnant, lactating, or of childbearing potential who are not using adequate contraceptive measures.
• Clinically unstable medical disease, including cardiovascular, hepatic, renal, gastrointestinal, pulmonary, metabolic, endocrine or other systemic disease. Subjects should be biochemically euthyroid to enter the study.

Where it is running

• Lindner Center of HOPE — Mason, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.